Skip to content

Study on the synergistic mechanism of Compound Kushen Injectioncombined with Photodynamic Therapy in the treatment of low advancedrectal cancerbased on STAT3 signaling pathway in tumormicroenvironment

Study on the synergistic mechanism of Compound Kushen Injectioncombined with Photodynamic Therapy in the treatment of low advancedrectal cancerbased on tumormicroenvironment

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078603
Enrollment
Unknown
Registered
2023-12-13
Start date
2024-01-01
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rectal cancer

Interventions

Photodynamic group,:Photodynamic therapy
Photodynamic + compound matrine group:Photodynamic therapy combined with compound matrine

Sponsors

Yichun people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: (1) patients with low advanced rectal cancer confirmed by colonoscopy, pathology and imaging; (2) no opportunity for surgery (for rectal stenosis and intestinal obstruction caused by huge tumors, which cannot be controlled by conventional treatment) or surgical conditions; (3) The patient strongly refused surgery. (4) unable to tolerate or refuse chemoradiotherapy; (5) No contraindications to photodynamic therapy: no allergy to photosensitizer, no serious coagulation disorders and other diseases that could affect the implementation of photodynamic therapy. (6) the expected survival time is more than 3 months; (7) The patients or their family members signed the informed consent of photodynamic therapy and compound matrine injection.

Exclusion criteria

Exclusion criteria: (1) patients allergic to photosensitizers; (2) patients with severe or uncontrolled cardiovascular and pulmonary diseases, or unstable vital signs due to various reasons; (3) patients with obvious coagulation dysfunction; (4) original hematoporphyria or other diseases aggravated by light, such as systemic lupus erythematosus, dermatomyositis, etc.; (5) patients with eye diseases who need to receive an ophthalmic light examination within the past one month; (6) Use with caution in pregnant and lactating women who plan to undergo surgery within 30 days; (7) no serious systemic diseases, such as uncontrolled active infection; (8) The patient was in a cachectic state, and the expected survival time was less than 3 months. (9) previous radiotherapy or chemotherapy.

Design outcomes

Primary

MeasureTime frame
remission rate;quality of life;

Countries

China

Contacts

Public ContactHuizhen Fan

Yichun people's Hospital

fanfanyc@163.com+86 139 7052 1169

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026